First Trust Advisors
MRNA icon

First Trust Advisors’s Moderna MRNA Stock Holding History

First Trust Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Sell
24,102
-2,368,591
-99% -$123M ﹤0.01% 2070
2026
Q1 		$122M Buy
2,392,693
+891,072
+59% +$41.6M 0.09% 288
2025
Q4 		$44.3M Buy
1,501,621
+469,089
+45% +$12.7M 0.03% 616
2025
Q3 		$26.7M Sell
1,032,532
-200,420
-16% -$5.59M 0.02% 810
2025
Q2 		$34M Buy
1,232,952
+318,183
+35% +$8.38M 0.03% 722
2025
Q1 		$25.9M Buy
914,769
+246,302
+37% +$8.74M 0.02% 780
2024
Q4 		$27.8M Buy
668,467
+31,645
+5% +$1.51M 0.02% 737
2024
Q3 		$42.6M Buy
636,822
+127,990
+25% +$11.8M 0.04% 558
2024
Q2 		$60.4M Sell
508,832
-95,514
-16% -$12.1M 0.06% 362
2024
Q1 		$64.4M Sell
604,346
-288,970
-32% -$29.1M 0.07% 386
2023
Q4 		$88.8M Buy
893,316
+102,251
+13% +$8.6M 0.1% 254
2023
Q3 		$81.7M Buy
791,065
+39,807
+5% +$4.44M 0.1% 261
2023
Q2 		$91.3M Buy
751,258
+82,476
+12% +$11M 0.1% 251
2023
Q1 		$103M Sell
668,782
-130,909
-16% -$21.6M 0.12% 222
2022
Q4 		$144M Buy
799,691
+172,731
+28% +$28.2M 0.17% 164
2022
Q3 		$74.1M Buy
626,960
+122,146
+24% +$18.5M 0.1% 295
2022
Q2 		$72.1M Sell
504,814
-2,459
-0.5% -$351K 0.09% 327
2022
Q1 		$87.4M Buy
507,273
+142,297
+39% +$24M 0.09% 297
2021
Q4 		$92.7M Sell
364,976
-114,511
-24% -$33.5M 0.09% 270
2021
Q3 		$185M Sell
479,487
-282,557
-37% -$104M 0.2% 137
2021
Q2 		$179M Buy
762,044
+227,063
+42% +$40.6M 0.19% 134
2021
Q1 		$70.1M Buy
534,981
+132,798
+33% +$19.2M 0.08% 327
2020
Q4 		$42M Buy
402,183
+40,468
+11% +$4.09M 0.06% 454
2020
Q3 		$25.6M Sell
361,715
-41,219
-10% -$2.87M 0.04% 472
2020
Q2 		$25.9M Sell
402,934
-36,012
-8% -$1.97M 0.04% 485
2020
Q1 		$13.1M Buy
+438,946
New +$10.1M 0.03% 577

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

First Trust Advisors's MRNA Position: Q2 2026 in Review

First Trust Advisors reduced its Moderna (MRNA) stake by 99% in Q2 2026, selling an estimated $123M and leaving 24,102 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

First Trust Advisors first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $185M in Q3 2021. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • First Trust Advisors held 24,102 shares of Moderna worth $1.69M as of Q2 2026.
  • First Trust Advisors sold 2,368,591 Moderna shares in Q2 2026, an estimated $123M.
  • Moderna made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #2070 holding.
  • First Trust Advisors first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • First Trust Advisors's Moderna position peaked at $185M in Q3 2021.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.